New Haven drug developer Achillion Pharmaceuticals Inc. has licensed its treatment for infectious blood disorders to a New Jersey bioscience company that will market the drug to China.
Achillion licensed its nucleoside reverse transcriptase inhibitor, named elvucitabine, for the treatment of both hepatitis B virus infection and human immunodeficiency virus (HIV) infection to GCA Therapeutics Ltd. of Jersey City.
GCA will clinically develop and market the treatment in mainland China, Hong Kong and Taiwan, both companies said in a statement. In return, Achillion will collect unspecified double-digit royalties on net sales of elvucitabine.
Achillion CEO Michael D. Kishbauch said the agreement opens the door to global sales of the treatment, which has been shown to effective in early clinical trials.
Achillion shares rose 6.6 percent to $2.58 in mid-morning trading.
Â
